

**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A polypeptide consisting of an amino acid sequence selected from the group consisting of:
  - (a) amino acids 37-140 of SEQ ID NO:9 (NBN 104);
  - (b) amino acids 39-140 of SEQ ID NO:9 (NBN 102); and
  - (c) amino acids 42-140 of SEQ ID NO:9 (NBN 99).
2. (Original) The polypeptide of claim 1, wherein the amino acid sequence consists of amino acids 37-140 of SEQ ID NO:9 (NBN 104).
- 3-7. (Cancelled)
8. (Original) A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
- 9-10. (Cancelled)
11. (New) The polypeptide of claim 1, wherein the amino acid sequence consists of amino acids 39-140 of SEQ ID NO:9 (NBN 102).
12. (New) The polypeptide of claim 1, wherein the amino acid sequence consists of amino acids 42-140 of SEQ ID NO:9 (NBN 99).

13. (New) The polypeptide of claim 2, wherein the polypeptide is glycosylated.
14. (New) The polypeptide of claim 11, wherein the polypeptide is glycosylated.
15. (New) The polypeptide of claim 12, wherein the polypeptide is glycosylated.
16. (New) A pharmaceutical composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.
17. (New) A pharmaceutical composition comprising the polypeptide of claim 11 and a pharmaceutically acceptable carrier.
18. (New) A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.
19. (New) A pharmaceutical composition comprising the polypeptide of claim 13 and a pharmaceutically acceptable carrier.
20. (New) A pharmaceutical composition comprising the polypeptide of claim 14 and a pharmaceutically acceptable carrier.
21. (New) A pharmaceutical composition comprising the polypeptide of claim 15 and a pharmaceutically acceptable carrier.